AstraZeneca Discontinues Brazikumab Inflammatory Bowel Disease Development Program
June 01 2023 - 2:59AM
Dow Jones News
By Anthony O. Goriainoff
AstraZeneca said Thursday that it was discontinuing the
brazikumab inflammatory bowel disease development program after
reviewing its development timeline as well as the context "of a
competitive landscape that has continued to evolve."
The Anglo-Swedish pharma giant said the timeline had been hurt
by delays that couldn't be mitigated following global events and
that no safety concerns were identified for patients in these
trials.
The company said that AbbVie had partly funded the program and
that this funding will now stop.
AstraZeneca said that the program was investigating an anti
IL-23 monoclonal antibody for the treatment of Crohn's disease and
ulcerative colitis.
Write to Anthony O. Goriainoff at
anthony.orunagoriainoff@dowjones.com
(END) Dow Jones Newswires
June 01, 2023 02:44 ET (06:44 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From May 2024 to Jun 2024
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Jun 2023 to Jun 2024
